Bridgefront Capital, LLC Akero Therapeutics, Inc. Transaction History
Bridgefront Capital, LLC
- $236 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
170Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$204 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$166 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$161 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$156 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$152 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.38B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...